Zydus Lifesciences Limited

Quick facts

Phase 3 pipeline

• Desidustat Oral Tablet · Hematology
  Desidustat inhibits prolyl hydroxylase domain-containing protein (PHD) enzymes to stabilize hypoxia-inducible factor (HIF) and increase endogenous erythropoietin production.
• Pertuzumab (Perjeta®) · Oncology
  Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.
• Pertuzumab (ZRC-3277) · Oncology
  Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.

Phase 2 pipeline

• Pegylated Interferon-α2b
• ZYIL1 capsule

Phase 1 pipeline

• ZY19489 Capsule
• ZYD1
• ZYDPLA1 tablet

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Zydus Lifesciences Limited portfolio CI brief
• Zydus Lifesciences Limited pipeline updates RSS